TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23592683

Group type: EXPERIMENTAL
Intervention: Multidimensional school-based lifestyle intervention including a playful physical activity program and lessons on nutrition, media use, and sleep.
Number of subjects: 652
Study: 21981813

Group type: EXPERIMENTAL
Intervention: Forward-viewing echoendoscope
Number of subjects: 58

Group type: COMPARATOR
Intervention: Oblique-viewing echoendoscope
Number of subjects: 58
Study: 18781660

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: PE combined with Cognitive Restructuring (PE/CR)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) and PE/CR
Number of subjects: 107
Study: 17446716

Group type: EXPERIMENTAL
Intervention: Combined oral and topical administration of lutein and zeaxanthin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral administration of lutein
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical administration of lutein and zeaxanthin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral administration of zeaxanthin
Number of subjects: 0
Study: 15023936

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg (C8)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg (C16)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg (V80)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Normalized index of renin release (renin/pharmacokinetic index)
Number of subjects: 16
Study: 11772257

Group type: EXPERIMENTAL
Intervention: Cilomilast (up to 15 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cilomilast
Number of subjects: 0
Study: 9834003

Group type: EXPERIMENTAL
Intervention: BMS‐188494 (PO2)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: BMS‐187745 (PO1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Model-independent AUC method
Number of subjects: 16
Study: 8158682

Group type: EXPERIMENTAL
Intervention: Plasma alpha-linolenic acid levels
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Plasma linoleic acid levels
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Eating red meat at least five times per week
Number of subjects: 240
Study: 2906863

Group type: EXPERIMENTAL
Intervention: Reinforcement for abstinence from illicit drug use
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combined intervention with reinforcement and aversive consequences
Number of subjects: 16

Group type: COMPARATOR
Intervention: Combined intervention with aversive consequences
Number of subjects: 16
Study: 5098326

Group type: EXPERIMENTAL
Intervention: bean-containing, high crude-fibre diet
Number of subjects: 10

Group type: COMPARATOR
Intervention: restricted crude-fibre content diet
Number of subjects: 10

Group type: COMPARATOR
Intervention: liquid chemically defined diet
Number of subjects: 10
Study: 31762105

Group type: EXPERIMENTAL
Intervention: Intervention (integrating smoking cessation treatment into usual AOD treatment)
Number of subjects: 896

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 896
Study: 31629118

Group type: EXPERIMENTAL
Intervention: Telelactation
Number of subjects: 203

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 203
Study: 28728986

Group type: EXPERIMENTAL
Intervention: Intracapsular total thyroid enucleation (ITTE)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Standard total thyroidectomy (STT)
Number of subjects: 224
Study: 26489030

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention and diabetes support and education
Number of subjects: 2118

Group type: COMPARATOR
Intervention: Diabetes support and education
Number of subjects: 2118
Study: 23405021

Group type: EXPERIMENTAL
Intervention: Subject-chosen activity group (n = 30)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Therapist-chosen activity group (n = 29)
Number of subjects: 59
Study: 21778171

Group type: EXPERIMENTAL
Intervention: TAU plus up to 12 sessions of individual rumination-focused CBT
Number of subjects: 42

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 42
Study: 19745765

Group type: EXPERIMENTAL
Intervention: Figitumumab (F, CP-751,871) 0.05-20 mg/kg in combination with paclitaxel 200 mg/m2 and carboplatin (AUC 6) q3 weeks for up to six cycles.
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Figitumumab (F, CP-751,871) 10 and 20 mg/kg dosing cohorts.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 42
Study: 16390351

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (300 mL)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Water (300 mL)
Number of subjects: 36
Study: 15327643

Group type: EXPERIMENTAL
Intervention: 0.03% chlorhexidine mouthrinse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.06% chlorhexidine mouthrinse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine mouthrinse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control rinse (without chlorhexidine)
Number of subjects: 0
Study: 11174009

Group type: EXPERIMENTAL
Intervention: Captopril (112 +/- 7 mg/day)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Doxazosin (8 +/- 1 mg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Captopril and Doxazosin (comparison)
Number of subjects: 28
Study: 9059480

Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol during CPAP via face mask
Number of subjects: 9

Group type: COMPARATOR
Intervention: Conventional nebulisation (control)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: CPAP at 10 cm H2O at a FGF rate of 50 l/min
Number of subjects: 9
Study: 8299431

Group type: EXPERIMENTAL
Intervention: Vitamin E (d‐alpha‐tocopherol; 900 mg/day)
Number of subjects: 25
Study: 3088266

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30087378

Group type: EXPERIMENTAL
Intervention: Semi-automated approach with automated detection of alveolar ridges (RapidNAM)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Conventional CAD/CAM-intraoral molding (stepwise manual design)
Number of subjects: 2
Study: 27040132

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg per day
Number of subjects: 12705

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12705
Study: 25159546

Group type: EXPERIMENTAL
Intervention: Fast-track care program (n = 40)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional perioperative care protocol (control group, n = 36)
Number of subjects: 76
Study: 21923981

Group type: EXPERIMENTAL
Intervention: Walnuts
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 20861207

Group type: EXPERIMENTAL
Intervention: Baseline measurement of LDL levels
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Baseline measurement of HDL levels
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Baseline measurement of TG levels
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Baseline measurement of Lpa levels
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Baseline measurement of homocysteine levels
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Baseline measurement of hs-CRP levels
Number of subjects: 221
Study: 18271912

Group type: EXPERIMENTAL
Intervention: Lamotrigine (fixed dose of 50 mg or 200 mg daily in Study 1; flexible dose of 100‐400 mg daily in Study 2; fixed dose of 200 mg daily in Studies 3, 4 and 5)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16163899

Group type: EXPERIMENTAL
Intervention: 250 mg Iclopid tablets (test formulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 250 mg Ticlid tablets (reference formulation)
Number of subjects: 0
Study: 14585916

Group type: EXPERIMENTAL
Intervention: COX-2-specific inhibitors (celecoxib or valdecoxib)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-specific NSAIDs
Number of subjects: 0
Study: 11789208

Group type: EXPERIMENTAL
Intervention: Zhenjian granule (ZJG)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 52
Study: 8892495

Group type: EXPERIMENTAL
Intervention: Positive frame
Number of subjects: 292

Group type: COMPARATOR
Intervention: Negative frame
Number of subjects: 292
Study: 1354367

Group type: EXPERIMENTAL
Intervention: Dichromats
Number of subjects: 7

Group type: COMPARATOR
Intervention: Trichromats
Number of subjects: 7
Study: 6327600

Group type: EXPERIMENTAL
Intervention: Low-dose pivmecillinam for up to three months
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 44
Study: 30903341

Group type: EXPERIMENTAL
Intervention: Successful revascularization (74%) in patients with FVH–DWI mismatch (80% success rate, 63/79 patients)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Favorable outcome (modified Rankin Scale score ≤ 2) for revascularization in patients with FVH–DWI mismatch
Number of subjects: 100

Group type: COMPARATOR
Intervention: Favorable outcome (modified Rankin Scale score ≤ 2) for revascularization in patients without FVH–DWI mismatch
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Favorable outcome after adjustment for NIHSS in patients with FVH–DWI mismatch
Number of subjects: 100

Group type: COMPARATOR
Intervention: Favorable outcome after adjustment for NIHSS in patients without FVH–DWI mismatch
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Favorable outcome after adjustment for DWI volume in patients with FVH–DWI mismatch
Number of subjects: 100

Group type: COMPARATOR
Intervention: Favorable outcome after adjustment for DWI volume in patients without FVH–DWI mismatch
Number of subjects: 100
Study: 30290983

Group type: COMPARATOR
Intervention: Commercial ultrasound transmission gel (USTG)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Glucomannan gel
Number of subjects: 193
Study: 27801405

Group type: EXPERIMENTAL
Intervention: High-frequency TMS (rTMS) at a frequency of 10 Hz
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Theta bursts stimulation (iTBS)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Both rTMS and iTBS
Number of subjects: 22
Study: 24813620

Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg/d (days 1-21)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Lenalidomide 5 mg/d (days 1-28)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg/d
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Lenalidomide 5 mg/d
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Lenalidomide-treated patients with RBC-TI ≥182 d
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 135
Study: 21988705

Group type: EXPERIMENTAL
Intervention: Aloe vera/olive oil cream
Number of subjects: 67

Group type: COMPARATOR
Intervention: Betamethasone 0.1% cream
Number of subjects: 67
Study: 20152239

Group type: EXPERIMENTAL
Intervention: Aged garlic extract plus supplement
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 18818191

Group type: EXPERIMENTAL
Intervention: Propofol (PPF)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Sevoflurane (SEVO)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 34

Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 34
Study: 15707855

Group type: EXPERIMENTAL
Intervention: Oral prednisolone 100 mg once daily for 72 hours
Number of subjects: 47

Group type: COMPARATOR
Intervention: IV hydrocortisone 100 mg every 6 hours for 72 hours
Number of subjects: 47
Study: 12608488

Group type: EXPERIMENTAL
Intervention: Alcohol (0.836 g/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: No alcohol (control)
Number of subjects: 16
Study: 10701468

Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 387

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 387
Study: 7852497

Group type: EXPERIMENTAL
Intervention: 25‐hydroxyvitamin D (25OHD; 20 micrograms/day for approximately 34 days)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no pretreatment with 25OHD)
Number of subjects: 41
Study: 1719708

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch
Number of subjects: 207

Group type: COMPARATOR
Intervention: Low-dose heparin
Number of subjects: 207
Study: 7284649

Group type: EXPERIMENTAL
Intervention: Phenytoin 300 mg per day for two weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30744149

Group type: EXPERIMENTAL
Intervention: Salmon with mashed potatoes (high GI)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Salmon with wholegrain pasta (low GI)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Veal with mashed potatoes (high GI)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Veal with wholegrain pasta (low GI)
Number of subjects: 25
Study: 27836430

Group type: COMPARATOR
Intervention: Monthly dosing with ranibizumab 0.3 mg every 4 weeks
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: TReat and EXtend without macular laser photocoagulation (TREX)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Treat and extend with angiography‐Guided macular Laser photocoagulation (GILA)
Number of subjects: 150
Study: 25778472

Group type: EXPERIMENTAL
Intervention: Manual study diameter (SDM) using RECIST
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Effective diameter (EDM)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: SDM change rate (SDM-CR)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: EDM change rate (EDM-CR)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: SDM-CR variability
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: EDM-CR variability
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Automated RECIST diameter (aRDM)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: EDM change significance
Number of subjects: 14
Study: 23142625

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 165
Study: 20473670

Group type: EXPERIMENTAL
Intervention: Hip resurfacing system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional prosthesis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 19372356

Group type: EXPERIMENTAL
Intervention: Ultrasound needle end point
Number of subjects: 81

Group type: COMPARATOR
Intervention: Neurostimulation needle end point
Number of subjects: 81
Study: 17291319

Group type: EXPERIMENTAL
Intervention: Initial optimism about achieving a 'normal life' after diagnosis
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Perception of normality over time
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Adjustment to new normal
Number of subjects: 32
Study: 15580211

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 12971817

Group type: EXPERIMENTAL
Intervention: Mixed training with concurrent production and sound identification training
Number of subjects: 9

Group type: COMPARATOR
Intervention: Production-only training
Number of subjects: 9
Study: 10658511

Group type: EXPERIMENTAL
Intervention: Visuo-spatial working memory tasks with additional load of retaining and recalling target appearance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visuo-spatial working memory tasks with articulatory suppression
Number of subjects: 0
Study: 7493457

Group type: EXPERIMENTAL
Intervention: NiSO4 0.1 M + MgSO4 0.1 M, 0.3 M, 0.5 M
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: NiCl2 0.1 M + MgCl2 0.3 M, 0.5 M, 1 M
Number of subjects: 110

Group type: COMPARATOR
Intervention: NiSO4 0.1 M, NiCl2 0.1 M, Na2SO4 0.3 M, NaCl 0.3 M
Number of subjects: 110
Study: 2088768

Group type: EXPERIMENTAL
Intervention: Romazarit (single oral doses ranging from 40 to 1500 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (capsules)
Number of subjects: 44
Study: 400313

Group type: EXPERIMENTAL
Intervention: Betamethasone phosphate 0.1%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clobetasone butyrate 0.1%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30027751

Group type: EXPERIMENTAL
Intervention: Kinesiology tape applied from origin to insertion (n=7)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Kinesiology tape applied from insertion to origin (n=8)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Kinesiology tape applied in the opposite direction after 1 week (insertion to origin [n=7] or origin to insertion [n=8])
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Kinesiology tape application (both directions)
Number of subjects: 15
Study: 28644761

Group type: EXPERIMENTAL
Intervention: Satir communication family therapy (CFT), 7 sessions
Number of subjects: 53

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 53
Study: 26489663

Group type: EXPERIMENTAL
Intervention: Adjunctive ketamine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 100
Study: 23435190

Group type: EXPERIMENTAL
Intervention: Formulation A (0.5% AR-12286 Ophthalmic Solution) once daily, both eyes for 8 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Formulation B (0.5% AR-12286 Ophthalmic Solution) once daily, both eyes for 8 days
Number of subjects: 18
Study: 21349260

Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/20mg or rosuvastatin 10mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: statin monotherapy (baseline)
Number of subjects: 0
Study: 19709412

Group type: EXPERIMENTAL
Intervention: Rye bread breakfast with bran
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Rye bread breakfast with intermediate fraction (B4)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Rye bread breakfast with sifted flour
Number of subjects: 32

Group type: COMPARATOR
Intervention: Wheat reference bread breakfast
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Rye bran (5g and 8g)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intermediate rye fraction (5g and 8g)
Number of subjects: 32
Study: 17627241

Group type: EXPERIMENTAL
Intervention: Single 9 mg/kg dose antithymocyte globulin (ATG)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Two 20 mg doses of basiliximab
Number of subjects: 155

Group type: COMPARATOR
Intervention: Conventional CsA triple therapy without induction
Number of subjects: 155
Study: 15128913

Group type: EXPERIMENTAL
Intervention: Air displacement plethysmography (ADP) using Siri's equation (%FM(ADP-Siri))
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Air displacement plethysmography (ADP) using predicted lung volume
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Air displacement plethysmography (ADP) using measured lung volume
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Air displacement plethysmography (ADP)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Air displacement plethysmography (ADP) in children <35 kg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Air displacement plethysmography (ADP) in girls
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Air displacement plethysmography (ADP) in boys
Number of subjects: 34
Study: 11876141

Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3

Group type: COMPARATOR
Intervention: Sulphasalazine
Number of subjects: 3

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 3
Study: 9717593

Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg i.v.)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fentanyl (100 micrograms i.v.)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 40
Study: 31857535

Group type: EXPERIMENTAL
Intervention: Stroke patients (intervention group)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 51
Study: 29178702

Group type: EXPERIMENTAL
Intervention: resin‐modified glass ionomer varnish ‐ Clinpro XT Varnish
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: fluoride‐containing self‐etch adhesive ‐ Clearfil SE Protect
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: glutaraldehyde‐containing etch‐and‐rinse adhesive ‐ Gluma 2 Bond
Number of subjects: 30
Study: 25872972

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 652

Group type: COMPARATOR
Intervention: Abacavir/lamivudine
Number of subjects: 652
Study: 24298524

Group type: EXPERIMENTAL
Intervention: SRP (Scaling and Root Planing) + DOX nanofibers
Number of subjects: 7

Group type: COMPARATOR
Intervention: SRP (Scaling and Root Planing) alone
Number of subjects: 7
Study: 19462498

Group type: EXPERIMENTAL
Intervention: Doxazosin (once-daily bedtime dose added to current medication)
Number of subjects: 611

Group type: COMPARATOR
Intervention: Control group (continued current medication)
Number of subjects: 611
Study: 17261454

Group type: EXPERIMENTAL
Intervention: Electronic monitoring of adherence
Number of subjects: 258

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 258
Study: 15161690

Group type: EXPERIMENTAL
Intervention: SU5416 (145 mg/m(2)) and dexamethasone premedication
Number of subjects: 36

Group type: COMPARATOR
Intervention: Dexamethasone alone
Number of subjects: 36
Study: 12389002

Group type: EXPERIMENTAL
Intervention: Rectal misoprostol 600 microg
Number of subjects: 1606

Group type: COMPARATOR
Intervention: Oxytocin 10 IU plus methylergometrine
Number of subjects: 1606

Group type: COMPARATOR
Intervention: Oxytocin 10 IU
Number of subjects: 1606
Study: 9872248

Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 8590531

Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo (0.9% saline solution)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Propafenone (nonresponders)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo (nonresponders)
Number of subjects: 182
Study: 2487537

Group type: EXPERIMENTAL
Intervention: Combination of nifedipine and prazosin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prazosin pretreatment
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nifedipine pretreatment
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prazosin as first drug and nifedipine as second drug
Number of subjects: 12
Study: 342924

Group type: EXPERIMENTAL
Intervention: Febuprol (3 capsules daily for 14 days)
Number of subjects: 50